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Severe acute renal failure (ARF) is a seri-
ous complication of critical illness. It aff ects 
5% of all intensive care unit admissions1 
and thousands of patients worldwide. 
Independently of underlying illness, ARF 
increases the risk of death fourfold and 
contributes to in-hospital mortality.2
Th e mainstay of treatment of severe ARF 
is renal replacement therapy (RRT). Such 
RRT comes in diff erent techniques, from 
conventional intermittent hemodialysis to 
slow extended daily dialysis, from perito-
neal dialysis to continuous RRT (CRRT).
Given such a ‘menu,’ it is not sur-
prising that there is controversy about 
which technique should be used. CRRT 
techniques currently form the stand-
ard of care in Australian intensive care 
units and are increasingly common in 
most developed countries for the treat-
ment of severe ARF in intensive care 
units1 but may not be as common in the 
United States.
If one chooses CRRT, the issue of dosage 
arises. In a recent landmark single-center 
randomized trial, Ronco and colleagues 
found that survival at 15 days aft er the last 
treatment was improved by an increase in 
the CRRT dose from 20 to 35 ml/kg/h.3 
Th us, increasing the dose of CRRT might 
increase survival. Th ere is further indirect 
evidence to support this notion. A retro-
spective study at the Cleveland Clinic4 
showed that patients receiving a greater 
dose of dialysis had increased survival. 
A randomized controlled trial5 showed 
daily dialysis to be better than second-
daily dialysis. Continuous hemofi ltration 
increased survival as compared with peri-
toneal dialysis.6 Finally, phase I human 
studies of high-intensity CRRT treatment 
(60–80 ml/kg/h) have shown clinical out-
come benefi ts.7 Despite these observations, 
the proposed increase in CRRT dose has 
not been widely embraced.1
Why practice has not changed
Th ere are several reasons why higher-dose 
CRRT as proposed in the Lancet study3 
has not been widely adopted. First, the 
study included a somewhat unusual 
patient population with an incidence of 
sepsis of only 15%, compared with the 
50%–60% incidence worldwide. Second, 
the conduct of the study took 5 years 
and, in the absence of randomization by 
blocks, could have had more patients in 
the intervention groups treated in the fi nal 
1 or 2 years when other supportive care 
was also advancing in quality, thus arti-
fi cially improving their outcome. Th ird, 
there is general concern about extrapolat-
ing the results of unblinded single-center 
studies to the worldwide intensive care 
population. By defi nition, the external 
validity of such single-center trials is 
very limited. Fourth, the additional cost 
of intensifying therapy (US$150–$200 
per day) is signifi cant. Fift h, continuous 
hemofiltration with post-dilution is a 
technically demanding CRRT technique 
(with higher blood fl ows needed to avoid 
hemoconcentration and shortened fi lter 
life), which is not currently used in most 
centers worldwide. Sixth, there is concern 
that increasing dialysis dose might lead 
to large and diffi  cult-to-assess nutrient 
losses. Seventh, no information on the 
ancillary care of patients (use of vaso-
pressors, style of mechanical ventilation, 
choice of antibiotics, use of steroids, and 
so on) was provided in the Lancet study.3 
Eighth, the study used a non-validated 
and short-term primary-outcome meas-
ure. Finally, the trial was conducted by 
a practitioner experienced in and com-
mitted to CRRT, a situation that ensured 
minimal time off  treatment but that can-
not be easily reproduced worldwide.
It is in this context that one should see 
the paper by Saudan and colleagues in 
this issue of Kidney International.8 Th e 
authors conducted a single-center rand-
omized controlled study in two intensive 
care units. Th ey randomized 206 patients 
either to continuous veno-venous hemo-
fi ltration at a rate of 1–2.5 l/h of replace-
ment fl uid or to continuous veno-venous 
hemofi ltration at the same rate plus addi-
tional dialysate fl ow of 1–1.5 l/h. Th ey 
found a significant increase in 28-day 
survival from 39% to 59% (P = 0.03) and 
a similar increase in 90-day survival. Th is 
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study represents yet another important 
contribution to the debate about the ‘right’ 
dose of RRT in severe ARF. It strengthens 
the notion that increasing the dose from 
approximately 20 ml/kg/h of urea clear-
ance to approximately 40 ml/kg/h might 
improve survival. However, like other 
single-center studies, it cannot be taken 
as conclusive evidence. Single-center 
studies, especially if unblinded, typically 
suffer from serious shortcomings and, 
by defi nition, have limited generalizabil-
ity. First, they are typically conducted by 
committed and dedicated practitioners. 
Th is increases the likelihood of a Haw-
thorne eff ect (the additional benefi cial 
eff ect of an overall treatment-independent 
increase in the attention and care given to 
recruited patients). Second, in this setting, 
the investigators are in a position to know 
the ongoing outcome of the trial, in eff ect 
conducting a ‘continuous interim analysis’ 
of treatment eff ect. Th is allows a degree of 
manipulation of sample size. It is of note 
that sample size was apparently set at 90 
patients in each group but more than a 
hundred patients were randomized to each 
group. Th ird, randomization in blocks of 
four or six in a single center allows guess-
ing of which treatment the next patient 
will receive. Fourth, balance at random-
ization cannot be ensured with a small 
sample size. Th us, in the study by Saudan 
et al.,8 the continuous veno-venous hemo-
fi ltration group had almost twice as many 
cases of cardiogenic shock (which has a 
particularly poor prognosis) and almost 
half the number of patients with ARF 
secondary to nephrotoxins (which has a 
better prognosis). In a small study where 
the outcome of three to four patients can 
aff ect the estimation of signifi cance, these 
diff erences matter a great deal. Th ere are 
other issues that invite caution, including 
the unusual method for the calculation of 
dose, its adjustment by approximation, 
the lack of standardized renal replace-
ment fl uid, the eff ect of pre-dilution on 
clearance, and so on. Yet the overriding 
question for clinicians is what to do next. 
Should they increase the dose of CRRT? 
Answering this question requires general 
considerations about what evidence might 
be suffi  cient for practice to change.
Why other studies are needed
Previous experience has repeatedly dem-
onstrated that single-center studies may 
produce results that cannot be replicated 
in larger multicenter studies. Intensive care 
unit examples include hypothermia for 
traumatic brain injury,9 supranormal oxy-
gen delivery in critically ill patients,10 and 
steroid therapy for late acute respiratory 
distress syndrome.11 As a result, nephrolo-
gists and intensivists should be reluctant 
to adopt treatments proven only in single-
center studies, unless the results are vali-
dated in larger multicenter studies.
On the other hand, if the preliminary 
studies described above are valid, appli-
cation of their fi ndings worldwide might 
save perhaps 15 000 lives per year. A 
study aimed at resolving this uncertainty 
about the impact of more intensive RRT 
on mortality is, therefore, of the high-
est priority. Two such large multicenter 
randomized controlled studies are now 
under way: the Veterans Administra-
tion/National Institutes of Health Acute 
Renal Failure Trial Network (ATN) study 
and the Australian and New Zealand 
Intensive Care Society/George Insti-
tute for International Health/Australian 
National Health and Medical Research 
Council Randomised Evaluation of Nor-
mal versus Augmented Level of RRT 
(RENAL) study.
The ATN and RENAL studies
Th e ATN study is a multicenter, prospec-
tive, randomized, parallel-group trial 
of two strategies for the management of 
RRT in ARF in critically ill patients. It is 
conducted within a network of approxi-
mately 30 tertiary-care Veterans Admin-
istration and university hospitals in the 
United States.
Patients with suspected ATN will 
be randomized to either an ‘intensive’ 
or a ‘conventional’ management strat-
egy (Figure 1). Within each group, 
depending on hemodynamic status, 
as assessed by the sequential organ 
failure assessment score, patients will 
receive either intermittent dialysis, or 
continuous therapy or sustained low-
effi  ciency dialysis (CRRT or slow low 
effi  ciency daily dialysis (SLEDD)). In 
patients randomized to the intensive-
strategy arm, the dose of treatment will 
Figure 1 | Schematic summary of treatment allocation and description for the Acute Renal 
Failure Trial Network (ATN) and Randomized Evaluation of Normal versus Augmented 
Level of RRT (RENAL) studies. SOFA, sequential organ failure assessment; CVS, cardiovascular 
component of the SOFA score; IHD, intermittent hemodialysis; Kt/V, dialysis dose; CVVHDF, 
continuous veno-venous hemodiafiltration; SLED, slow low-efficiency dialysis; CRRT, continuous 
renal replacement therapy.
 
 
Randomization (1:1) 
Intensive management strategy
If hemodynamically stable (SOFA CVS score: 0–2),
IHD 6 times/week (target Kt/V = 1. 2 –1.4/session)
If hemodynamically unstable (SOFA CVS score: 3–4)
CVVHDF at 35 ml/kg/h or
SLED 6 times/week (target Kt/V = 1.2 –1.4  /session)
Conventional management strategy
If hemodynamically stable (SOFA CVS score: 0 2),
IHD 3 times/week (target Kt/V = 1.2 1.4/session)
If hemodynamically unstable
 (SOFA CVS score: 3 – 4)
CVVHDF at 20 ml/kg/h or
SLED 3 times/week (target Kt/V = 1.2 –1.4/session)
ATN study
RENAL study
Randomization (1:1)
Normal-dose CRRT
25 ml/kg/h of effluent generation 
in CVVHDF mode with post-
dilution replacement fluid
Augmented-dose CRRT
40 ml/kg/h of effluent generation 
in CVVHDF mode with post-
dilution replacement fluid
–
,
–
,
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be greater (for CRRT, this will mean a 
dose increase from 20 to 35 ml/kg/h of 
estimated urea clearance). Th e primary 
end point for the ATN study is 60-day 
all-cause mortality. Th e investigators 
have estimated that 1164 subjects need 
to be randomized to show a 10% abso-
lute reduction in mortality from 55% to 
45% with a power of 90% at a two-sided 
signifi cance level of 0.05, allowing for 
a dropout rate of 10%. Th e ATN study 
is now well under way, and it is likely it 
will be completed in 2007. Th e results 
might be available in 2008.
The RENAL study is a multicenter, 
open-label, parallel-group, randomized, 
controlled trial of an ‘augmented’ CRRT 
regimen to deliver a dose of 40 ml/kg/h 
of estimated urea clearance, compared 
with ‘normal’ CRRT at a dose of 25 ml/
kg/h in critically ill patients with severe 
ARF (Figure 1). Th e dose of 25 ml/kg/h 
represents current average practice in 
Australia and New Zealand. Th e primary 
aim of the study is to compare the eff ects 
of these two CRRT doses on all-cause 
mortality. Th e RENAL study will rand-
omize 1500 patients. Th is study will have 
a 90% power to detect an 8.5% absolute 
reduction in 90-day mortality at an α of 
0.05, assuming a 90-day mortality of 60% 
in controls.
The study is being conducted by the 
same group of investigators who com-
pleted the low-dose dopamine trial12 and 
the Saline versus Albumin Fluid Evaluation 
(SAFE) trial13 and who are conducting a 
6000-patient trial of glycemic control in 
intensive care units called NICE (normo-
glycemia in intensive care evaluation).14 
Like these three trials, the RENAL study 
takes the form of a large simple-design 
trial with broad inclusion criteria.
Th e RENAL study is now under way 
and is scheduled to fi nish by the end of 
2007 or by early 2008. Th e results should 
be available in 2008.
Why we should wait
The ATN and RENAL studies are the 
largest randomized controlled trials of 
RRT dose ever attempted. Th ey are of the 
highest possible methodological quality 
and will provide powerful, widely appli-
cable, generalizable information about 
the eff ect of dose and technique on the 
outcome of critically ill patients with 
ARF. Because of their design, their size, 
the involvement of multiple centers, their 
statistical power, the use of independ-
ent Data Safety Monitoring Boards, the 
application of preset rules concerning 
interim analysis, and the use of robust, 
predefi ned outcome measures, they will 
probably provide suffi  cient evidence to 
justify a change in practice, if positive. 
Irrespective of the findings, they will 
provide valuable data on many aspects 
of RRT (secondary outcomes, technique, 
timing of start of RRT, anticoagulation, 
risk of bleeding, complications, fi lter life, 
and the like), which will inform practice 
for years to come. Th e prudent clinician 
would do well to wait until the release 
of the results of these two trials before 
deciding what is ‘best technique’ and 
‘best dose’ of RRT in severe ARF.
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